Monsanto Company MON has carved a name for itself in the global agricultural chemicals’ industry. By conducting trade, the company tries to enhance the yield and quality of several commercial and non-commercial agricultural crops such as cotton, soybean and corn.
Over the last 3 months, MON’s shares recorded a return of 1.50%-outperforming the negative return of 1.17% recorded by the Zacks categorized Agriculture/Products industry.
Currently, MON has a Zacks Rank #2 (Buy), but that could definitely change after the release of its upcoming earnings report.You can see the complete list of today’s Zacks #1 Rank stocks here.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: MON reported adjusted earnings of 21 cents per share in first-quarter fiscal 2017, on an ongoing basis. The Zacks Consensus Estimate was of loss of 4 cents per share.
Revenue: MON posted revenues of $2,650 million in first-quarter fiscal 2017, higher than the year-ago tally of $2,219 million.
Key Factors: MON anticipates to generate adjusted earnings within the range of $4.50-$4.90 per share in fiscal 2017, on an ongoing basis. While adjusted earnings for second-quarter fiscal 2017 is expected to lie within the range of 20-50 cents, on an ongoing basis.
MON aims to underpin its business on the back of improved core seeds and genomics business, strategic management of agricultural productivity segment’s trade, meaningful restructuring and appropriate investments.
The company perceives that its agreement to combine with Bayer AG BAYRY would open up a trench of the deal by the end of calendar year 2017.
Stock Price: At the time of writing, the stock price of MON was up nearly 0.43% ($0.45) in the pre-market trade on Nasdaq. Clearly the initial reaction to the release is positive. We view the company’s better-than-expected first-quarter fiscal 2017 results as the primary reason responsible for this positive sentiment.
Check back our full write up on this MON earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment